Compare Eli Lilly And Co (LLY) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Boston Beer Company Inc — how do they compare? Eli Lilly And Co trades at $1,174.99 (market cap $1.04T), while Boston Beer Company Inc trades at $171.26 (market cap $1.76B). The key difference: Eli Lilly And Co is far larger — about 590.9× Boston Beer Company Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Boston Beer Company Inc for 59 Days on average.
| LLY | SAM | |
|---|---|---|
Market Cap | $1.04T | $1.76B |
Volume | 3,064,878 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $1.28K | $260.05 |
52-Week Low | $799.57 | $161.08 |
Typical Hold Time | 93 Days | 59 Days |
Enterprise Value | $1.09T | $1.53B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Boston Beer Company (SAM) trades at $170.53, up 1.41% with a bullish technical signal despite recent earnings misses. The stock shows mixed fundamentals with a P/E of 22.66 and negative net margin of -3.64%, though operating cash flow remains strong at $270M. Recent news highlights brand innovation including new cocktail products and marketing partnerships, while analyst consensus leans heavily toward Hold with a $204.44 price target.
SAM faces headwinds from volume declines and cost pressures, but brand investments and new product launches offer growth potential. The stock trades near key support at $169 with institutional interest increasing. Upside depends on successful innovation execution, while downside risks include persistent margin pressure and competitive threats in the beverage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
